Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jukka Sairanen is active.

Publication


Featured researches published by Jukka Sairanen.


Scandinavian Journal of Urology and Nephrology | 2009

Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it

Jukka Sairanen; Mikael Leppilahti; Teuvo L.J. Tammela; Ilkka Paananen; Sirpa Aaltomaa; Kimmo Taari; Mirja Ruutu

Objective. Painful bladder syndrome/interstitial cystitis (PBS/IC) is an inflammatory bladder disease of unknown origin. Symptoms of PBS/IC compromise patients’ quality of life (QoL). This study evaluated a health-related quality of life (HRQoL) questionnaire in PBS/IC. Material and methods. 151 patients with PBS/IC filled in the HRQoL questionnaire before and after the treatment. Of these, 87 patients participated in a 3-month randomized study testing intravesical dimethyl sulfoxide (DMSO) and bacille Calmette–Guérin (BCG) and 64 patients took part in a 6-month randomized study evaluating oral cyclosporine A (CyA) and pentosan polysulfate sodium (PPS). The changes in HRQoL questionnaire were evaluated with respect to the changes in global response assessment (GRA). Results. The results of the HRQoL questionnaire reflected well the post-treatment GRA. Patients responding to their treatment had improved QoL. CyA treatment had more impact on emotional well-being, social functioning, activity limitation days, pain and physical capacity than PPS treatment (p<0.05). More patients responded to DMSO than BCG treatment according to GRA (p<0.01), but the results in HRQoL questionnaire were equal after DMSO and BCG treatments. Conclusions. The HRQoL questionnaire can be used in evaluating QoL in PBS/IC patients. Treatment of PBS/IC had obvious effects on QoL.


Urology | 2008

Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium.

Jukka Sairanen; Kristina Hotakainen; Teuvo L.J. Tammela; Ulf-Håkan Stenman; Mirja Ruutu

OBJECTIVES To measure urinary epidermal growth factor (EGF) and interleukin-6 (IL-6) levels in painful bladder syndrome/interstitial cystitis (PBS/IC) patients randomized to either cyclosporine A (CyA) or pentosan polysulfate sodium (PPS) treatment for 6 months and compare the results with treatment response. METHODS Urine samples from PBS/IC patients were collected before (n = 37) and after treatment (n = 34). The concentration of EGF was determined by an in-house immunofluorometric assay and that of IL-6 by the Immulite assay. The clinical response to treatment was determined by the subjective global response analysis (GRA, scale 1 to 6). Participants who reported categories 5 (much better) or 6 (cured) were considered responders. RESULTS According to GRA, 72% of CyA patients and 16% of PPS patient responded to their treatment (P <0.001). In the CyA group, post-treatment urinary EGF levels were significantly reduced (from 35 +/- 15.8 to 28.3 +/- 17.9 ng/mg creatinine; P <0.034), whereas the urinary IL-6 levels were not affected by CyA or PPS treatment in the whole group. In older patients (aged more than 52 years) who had higher IL-6 levels and longer duration of disease, these were reduced by successful CyA therapy. CONCLUSIONS Treatment of PBS/IC patients with CyA resulted in significantly decreased urinary levels of EGF. Interleukin-6 levels did not change significantly in all treated patients after either CyA or PPS treatment, but in older patients the levels were reduced after CyA treatment.


Acta Oncologica | 2013

Implementation of adaptive radiation therapy for urinary bladder carcinoma: Imaging, planning and image guidance

Laura Tuomikoski; Juha Korhonen; Juhani Collan; Jani Keyriläinen; Harri Visapää; Jukka Sairanen; Kauko Saarilahti; Mikko Tenhunen

Abstract Background. Adaptive radiation therapy (ART) for urinary bladder cancer has emerged as a promising alternative to conventional RT with potential to minimize radiation-induced toxicity to healthy tissues. In this work we have studied bladder volume variations and their effect on healthy bladder dose sparing and intrafractional margins, in order to refine our ART strategy. Material and methods. An online ART treatment strategy was followed for five patients with urinary bladder cancer with the tumors demarcated using Lipiodol®. A library of 3–4 predefined treatment plans for each patient was created based on four successive computed tomography (CT) scans. Cone beam CT (CBCT) images were acquired before each treatment fraction and after the treatment at least weekly. In partial bladder treatment the sparing of the healthy part of the bladder was investigated. The bladder wall displacements due to bladder filling were determined in three orthogonal directions (CC, AP, DEX-SIN) using the treatment planning CT scans. An ellipsoidal model was applied in order to find the theoretical maximum values for the bladder wall displacements. Moreover, the actual bladder filling rate during treatment was evaluated using the CBCT images. Results. In partial bladder treatment the volume of the bladder receiving high absorbed doses was generally smaller with a full than empty bladder. The estimation of the bladder volume and the upper limit for the intrafractional movement of the bladder wall could be represented with an ellipsoidal model with a reasonable accuracy. Observed maximum growth of bladder dimensions was less than 10 mm in all three orthogonal directions during 15 minute interval. Conclusion. The use of Lipiodol contrast agent enables partial bladder treatment with reduced irradiation of the healthy bladder volume. The ellipsoidal bladder model can be used for the estimation of the bladder volume changes and the upper limit of the bladder wall movement during the treatment fraction.


Cancer Imaging | 2018

11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)

Antti Salminen; Ivan Jambor; Harri Merisaari; Otto Ettala; Johanna Virtanen; Ilmari Koskinen; Erik Veskimäe; Jukka Sairanen; Pekka Taimen; Jukka Kemppainen; Heikki Minn; Peter J. Boström

BackgroundTo evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC).MethodsEighteen patients were prospectively enrolled. Fifteen treatment naive patients underwent 11C-acetate PET/MRI before transurethral resection of bladder tumor (TUR-BT) for primary tumor evaluation. Five patients with muscle invasive BC were imaged after NAC and prior to radical cystectomy (RC) with extended pelvic lymph node dissection (ePLND) for NAC treatment response evaluation. Two patients were part of both cohorts. 11C-acetate PET/MRI findings were correlated with histopathology. Accuracy for lymph node detection was evaluated on patient and the ePLND template (10 regions) levels.ResultsThe sensitivity, specificity and accuracy of 11C-acetate PET/MRI for the detection of muscle invasive BC was 1.00, 0.69 and 0.73 while the area under the receiver operating characteristic curve (95% confidence interval) was 0.85 (0.55–1.0), respectively. All five NAC patients underwent chemotherapy as planned and 11C-acetate PET/MRI correctly staged three patients, overstaged one and understaged one patient compared with RC and ePLND findings. A total of 175 lymph node were removed, median of 35 (range, 27–43) per patient in five patients who had RC and ePLND while 12 (7%) harboured metastases. Sensitivity, specificity, accuracy and AUC for N-staging were 0.20, 0.96, 0.80 and 0.58 on the ePLND template (10 regions) level.Conclusions11C-acetate PET/MRI is feasible for staging of BC although sensitivity for the detection of nodal metastases is low. Monitoring response to NAC shows promise and warrants evaluation in larger studies.Trial registrationClinicalTrials.gov Identifier: NCT01918592, registered August 8 2013


Scandinavian Journal of Urology and Nephrology | 2017

Male urethral reconstruction using vagina as a substitute in a 45X/46XY case.

Seppo Taskinen; Riikka Järvinen; Maija Kolehmainen; Jukka Sairanen

Repair of failed hypospadias surgery is a challenging operation, which aims to restore normal voiding function without compromising erectile function or penile appearance. A twostage operation is required if a urethra is markedly scarred or penile skin is insufficient to form a pedicled flap. A free graft, often from buccal mucosa, is preferred for urethral reconstruction. However, if the urethral defect is long, other graft donor sites may be required. In some male patients, especially with proximal hypospadias or disorders of sex development (DSDs), a remnant of vagina may be available. In males, it is a diverticulum-like extension from the prostatic urethra, varying in length from 10mm to 8 cm [1]. Its use as a pedicled flap in urethroplasty has been described previously [2]. However, as far as we know, there are no previous reports on the use of vagina as a free graft donor site.


European Urology | 2008

Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC Proposal

Joop P. van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L. Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul P. Irwin; Svend Aage Mortensen; Arndt van Ophoven; John L. Osborne; Ralph Peeker; Benedikte Richter; Claus R. Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele


European Urology | 2004

Primary Evaluation of Patients Suspected of Having Interstitial Cystitis (IC)

Jørgen Nordling; F.H Anjum; J.J Bade; Kirsten Bouchelouche; Pierre Bouchelouche; Mauro Cervigni; Suzy Elneil; Magnus Fall; T Hald; T. Hanus; H Hedlund; Gero Hohlbrugger; Thomas Horn; S Larsen; M Leppilahti; Svend Aage Mortensen; M Nagendra; P.D Oliveira; John L. Osborne; Claus R. Riedl; Jukka Sairanen; Martina Tinzl; Jean Jacques Wyndaele


The Journal of Urology | 2004

LONG-TERM OUTCOME OF PATIENTS WITH INTERSTITIAL CYSTITIS TREATED WITH LOW DOSE CYCLOSPORINE A

Jukka Sairanen; Tapio Forsell; Mirja Ruutu


Neurourology and Urodynamics | 2007

Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: A prospective study with cyclosporine A and pentosan polysulfate sodium†

Jukka Sairanen; Teuvo L.J. Tammela; Mikael Leppilahti; Markku Onali; Tapio Forsell; Mirja Ruutu


Journal of Pediatric Urology | 2014

Role of visual internal urethrotomy in pediatric urethral strictures

Ene Launonen; Jukka Sairanen; Mirja Ruutu; Seppo Taskinen

Collaboration


Dive into the Jukka Sairanen's collaboration.

Top Co-Authors

Avatar

Mirja Ruutu

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antti Salminen

Lappeenranta University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Otto Ettala

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Heikki Minn

Turku University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge